Search

Artificial intelligence is rapidly entering pharmaceutical manufacturing through predictive analytics, process analytical technology, continuous manufacturing platforms, and data-driven quality control. These developments promise earlier detection of process deviation, adaptive optimization of critical process parameters, and more responsive assurance of critical quality attributes. Yet the dominant regulatory and quality vocabulary remains anchored in Quality-by-Design, a paradigm built around pre-defined knowledge, structured risk assessment, and validated control strategies. The central problem is that AI-assisted manufacturing systems do not behave like conventional pharmaceutical processes governed solely through fixed design spaces. Machine learning models may change performance as data distributions shift, as sensors age, as materials vary, or as feedback loops alter the operating environment. This creates a governance gap between the static logic of pre-validation and the dynamic reality of algorithmic decision-making. This critical conceptual review examines whether Quality-by-Design remains sufficient for AI-assisted pharmaceutical manufacturing. It argues that QbD is still necessary but no longer sufficient because it was designed for processes whose boundaries, models, and control logic can be defined before routine operation. AI-assisted systems require an additional governance logic capable of supervising data, models, explanations, adaptation, and accountability throughout the product lifecycle. The review develops the concept of Quality-by-Intelligence as a forward-looking governance framework. QbI does not discard QbD; rather, it extends it by embedding data stewardship, model lifecycle management, explainable decision-making, adaptive risk control, and regulatory translation into the pharmaceutical quality system. Its purpose is to govern not only the manufacturing process, but also the intelligence layer that increasingly mediates quality decisions. Quality-by-Intelligence reframes pharmaceutical quality as an adaptive, evidence-generating, and accountable system rather than a one-time design achievement. The transition will require new regulatory expectations, new validation evidence, new operator competencies, and stronger collaboration between industry, regulators, and academic experts. Without this shift, AI may be deployed into manufacturing faster than the quality systems needed to govern it.

Nanomedicines promise therapeutic advantages that are difficult to achieve with conventional dosage forms, including improved targeting, altered pharmacokinetics, protected delivery of fragile payloads, and platform adaptability across drug classes. Yet these benefits depend on manufacturing systems that can repeatedly generate nanoscale products within narrow physicochemical and biological performance windows. The central difficulty is that small changes in process conditions can produce disproportionate changes in particle size, morphology, surface properties, encapsulation efficiency, release behaviour, and biological interaction. Despite decades of academic activity, the translation of nanomedicine from laboratory prototypes to routine clinical and industrial products remains limited. Many formulations are optimised in small batches under conditions that are poorly suited to pilot or commercial production. As a result, promising nanocarriers may fail not because their therapeutic concept is weak, but because their quality attributes cannot be reproduced reliably at scale. The analysis identifies a systemic mismatch between laboratory-optimised formulation methods and industrial requirements for control, documentation, comparability, continuous monitoring, and GMP-ready reproducibility. Four tables synthesise manufacturing platforms, scale-up fragility points, reproducibility challenges, and regulatory or industrial barriers. Together, these syntheses support a translational quality framework centred on process understanding, platform logic, critical quality attributes, and regulatory co-evolution. The review concludes that nanomedicine translation cannot rely on linear scale-up assumptions. Robust translation requires a shift toward platform-based manufacturing, quality-by-design development, integrated process analytical technology, orthogonal characterisation, predictive scale-down models, and shared regulatory learning. Nanomedicines will become clinically credible only when therapeutic innovation is matched by reproducible, affordable, and auditable manufacturing systems.

Pharmaceutical technologies are commonly designed and validated under controlled assumptions about materials, processes, supply continuity, and patient use. Yet once products enter development, scale-up, manufacturing, distribution, and real-world use, they encounter variability that cannot be fully predicted or eliminated. Supply disruptions, raw-material shifts, equipment drift, environmental fluctuations, and heterogeneous patient behaviours can all disturb the intended relationship between product design and therapeutic performance. The prevailing pharmaceutical design paradigm has made important advances through quality-by-design, risk management, and process analytical technology. However, it often treats variability primarily as a deviation from a predefined optimum rather than as a persistent condition of system operation. This creates a risk that pharmaceutical technologies become highly optimised for expected conditions but brittle when exposed to unfamiliar combinations of supply, process, and patient-level stressors. This article proposes an original resilience-theoretic framework for pharmaceutical technology design. The framework argues that technologies should be designed not only to meet specifications under normal conditions, but also to absorb disturbance, adapt to changing conditions, maintain acceptable performance, and degrade gracefully when ideal operation is no longer possible. It therefore reframes resilience as a design objective rather than a post hoc recovery capability. The article contributes a conceptual structure for aligning pharmaceutical technology design with the realities of variability. It shows how resilience thinking can connect supply robustness, process adaptability, and patient-centred performance into a single design logic. Designing for resilience represents a shift from static robustness toward dynamic adaptability, offering a pathway to pharmaceutical technologies that remain reliable, usable, and therapeutically meaningful under changing conditions.

Continuous pharmaceutical manufacturing has matured from a technical alternative to batch production into a strategically important manufacturing paradigm. Its promise lies in integrated material flow, smaller production footprints, improved process understanding, flexible scale-out, and the possibility of real-time quality assurance. Yet the quality systems used to govern continuous manufacturing often remain conceptually anchored in batch-era assumptions. The central problem addressed in this article is the mismatch between continuous manufacturing’s dynamic data environment and the inherited quality logic of discrete batch testing, fixed specifications, and retrospective release decisions. In batch quality logic, quality is often treated as a property confirmed after production. In continuous manufacturing, however, quality must be interpreted, predicted, and controlled while the process is still unfolding. This article proposes Lifecycle Intelligence as a theory-driven model for rethinking quality in continuous pharmaceutical manufacturing systems. Lifecycle Intelligence is defined as a quality paradigm in which process data, predictive models, control strategies, and lifecycle learning mechanisms are integrated to maintain quality dynamically across development, validation, commercial production, and post-approval improvement. The model shifts attention from isolated product release to continuous quality cognition. The argument advanced is that continuous manufacturing cannot reach its full quality and regulatory potential if it is governed primarily by batch quality logic. A lifecycle intelligence paradigm is needed to convert continuous data streams into validated quality decisions. This shift will require not only technical advances, but also new validation practices, model governance structures, regulatory dialogue, and workforce capabilities.

Pharmaceutical quality is often operationalized through stability testing, in which products are exposed to defined temperature and humidity conditions to support shelf-life assignment. This practice is indispensable, but it can create a narrow interpretation of quality when stability under controlled chamber conditions is treated as evidence of real-world performance. Products do not move through idealized chambers; they move through development uncertainty, manufacturing variability, distribution stress, and patient-level handling. This article argues that the dominant stability paradigm has encouraged a conceptual conflation between stability and robustness. Stability testing primarily asks whether a product remains within specification under predefined storage conditions for a defined period. Robustness, by contrast, asks whether the product–process–use system can continue to deliver acceptable quality when exposed to interacting stresses across the full lifecycle. The objective of this article is to develop an Integrated Robustness Theory for pharmaceutical products. The theory frames robustness as a system-level property spanning development, manufacturing, storage, and administration. It proposes that quality should be understood not only as shelf-life survival but also as resilient performance under realistic and combined stress conditions. The article critiques the limits of stability testing, defines robustness dimensions across lifecycle phases, and develops a systems-based framework for translating robustness into development strategy, manufacturing control, storage evaluation, and administration design. Three tables are used to map lifecycle robustness dimensions, storage stress gaps, and the integrated theory. The central conclusion is that pharmaceutical quality assurance must move beyond shelf-life thinking toward lifecycle robustness thinking.